NCT02342587View on ClinicalTrials.gov

Safety and Clinical Activity of Lapatinib in Patients With HER2-positive Refractory Advanced Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

December 3, 2014

Primary Completion Date

January 31, 2016

Study Completion Date

August 21, 2016

Conditions
HER2-positive Refractory Advanced Cancer
Interventions
DRUG

Lapatinib

Patients will be treated with oral lapatinib 1250mg once daily for 21 days.

Trial Locations (1)

Unknown

Samsung Medical Center, Seoul

All Listed Sponsors
lead

Samsung Medical Center

OTHER

NCT02342587 - Safety and Clinical Activity of Lapatinib in Patients With HER2-positive Refractory Advanced Cancer | Biotech Hunter | Biotech Hunter